Glynova-M 2 Tablet SR is a combination oral antidiabetic medication containing Glimepiride 2mg and Metformin 500mg, formulated for sustained release. It is primarily indicated for the management of type 2 diabetes mellitus in patients whose blood glucose levels are inadequately controlled by diet, exercise, and monotherapy. Glimepiride, a sulfonylurea class agent, acts by stimulating pancreatic beta cells to increase insulin secretion, thereby lowering blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization. The sustained-release formulation allows for a gradual release of the active ingredients, promoting better glycemic control with reduced gastrointestinal side effects commonly associated with immediate-release metformin. Glynova-M 2 Tablet SR should be used as part of a comprehensive diabetes management plan, including diet modification and regular physical activity. Dosage must be individualized based on patient response and tolerability, with careful monitoring of blood glucose and renal function. Contraindications include severe renal impairment, metabolic acidosis, and hypersensitivity to components. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and rarely, lactic acidosis. Patients should be advised to adhere strictly to prescribed regimens and report any unusual symptoms promptly.